Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Other financing activities (2011 - 2026)

Cytosorbents posted quarterly Other financing activities of $544000.0 for Q1 2026, down 33.5% year-on-year from $818000.0 in Q1 2025, and down 38.6% on a QoQ basis from $886000.0 in Q4 2025.

Cytosorbents (CTSO) has 5 years of Other financing activities data on file, last reported at $544000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Other financing activities fell 33.5% year-over-year to $544000.0; the trailing twelve-month figure through Mar 2026 stood at $2.5 million (up 204.28% YoY), and the FY2025 full-year result was $2.8 million, down 26.46% from the prior year.
  • Other financing activities for Q1 2026 stood at $544000.0, down from $886000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $886000.0 in Q4 2025 and bottomed at $488000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Cytosorbents 28.81 Mn 24.01 Mn 6.13 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 544,000.00
Mar 31, 2026 544,000.00
Dec 31, 2025 886,000.00
Dec 31, 2025 886,000.00
Sep 30, 2025 488,000.00
Sep 30, 2025 488,000.00
Jun 30, 2025 571,000.00
Jun 30, 2025 571,000.00
Mar 31, 2025 818,000.00
Mar 31, 2025 818,000.00
Mar 31, 2018 147,988.00
Mar 31, 2018 147,988.00
Jun 30, 2017 1,560.00
Jun 30, 2017 1,560.00
Sep 30, 2011 2,188.00
Sep 30, 2011 2,188.00